MediPharm Labs Corp. (OTCQX: MEDIF) (TSX: LABS) a worldwide leader in specialized, analysis-driven pharmaceutical-excellent cannabis extraction, distillation and derivative solutions, right now announced it will provide cannabis concentrate solutions in Denmark to two new healthcare cannabis clients beneath two separate white-label agreements. These clients will be serviced by each GMP authorized facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ initial provide agreements for the export of completed solutions to Denmark.
Denmark granted individuals legal access to cannabis-primarily based medicinal solutions two years ago as portion of a 4-year pilot plan. The plan gives individuals with secure item access and national overall health authorities with patient information that they can use to fully grasp usage and efficacy. According to info complied by New Frontier Information and the Danish Ministry of Overall health, more than two,one hundred individuals (mainly girls among the ages of 42-64) received cannabis-primarily based medicinal solutions from 429 prescribing physicians beneath this plan in 2019.
“The express objective of establishing a multi-jurisdictional, GMP-certified production capability is to lead the worldwide cannabis marketplace for medicinal, wellness and adult use applications and these agreements represent one more step forward in realizing our ambitions,” mentioned Pat McCutcheon, CEO, MediPharm Labs. “Getting in on the ground floor of the Danish healthcare marketplace with new and revolutionary healthcare cannabis focused solutions positions us for more development in Europe and adds to MediPharm Labs all-crucial physique of understanding that we are leveraging to improve the style of our formulations for individuals and shoppers everywhere.”
Beneath the agreements, 1 which has an initial two-year term and the second a 1-year term – each topic to renewal, MediPharm Labs will provide a complete variety of specially formulated CBD and THC cannabis oil solutions that will be white-labeled for distribution.
MediPharm Labs anticipates delivery to its clients to commence in October 2020, pending regulatory approval by applicable overall health authorities.
GMP Certification Ignites Development for MediPharm Labs Australia
“Since the starting of 2020, MediPharm Labs Australia has secured quite a few pretty appealing domestic and international provide agreements with higher excellent partners, now such as new clients in Denmark,” mentioned Warren Everitt, CEO, MediPharm Labs Australia. “This volume and the pace of new small business wins are a clear and crucial validation of our choice to create a GMP certified cannabis extraction facility provide chain for planet markets and a testament to MediPharm Labs increasing profile and reputation. We appear forward to ramping up production beneath all of these agreements.”
MediPharm Labs Australia received its Excellent Manufacturing Practice (“GMP”) certificate from the Therapeutic Goods Association in May well 2020, which enables it to sell cannabis APIs and completed solutions to nations across the EU, such as Denmark. The Organization entered into its initial European white-label cannabis provide agreement that very same month with Therismos Restricted.
About Denmark’s Healthcare Cannabis Market place
Denmark launched its 4-year healthcare cannabis pilot plan on January 1st, 20181. Post-harvest Excellent Manufacturing Processes (GMP) is expected for distribution of healthcare cannabis solutions in Denmarktwo.
By way of the plan, physicians can prescribe healthcare cannabis for all purposes and are guided by suggestions in 4 places: discomfort triggered by several sclerosis, discomfort triggered by spinal cord harm, side effects from chemotherapy therapy and neuropathic discomfort that is due to brain, spinal cord or nerve harmthree. The suggestions published by the Danish Medicines Agency are primarily based on an substantial overview of literature as properly as assessments of: cannabis schemes in the Netherlands, Canada and Israel prior cannabis drug approvals in Europe and the US and scientific proof by the National Academy of Sciences (USA, 2017).
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical excellent cannabis oil and concentrates and sophisticated derivative solutions using a Excellent Manufacturing Practices certified facility with ISO common constructed clean rooms. MediPharm Labs has invested in an professional, analysis-driven group, state-of-the-art technologies, downstream purification methodologies and objective-constructed facilities with 5 main extraction lines for delivery of pure, trusted and precision -dosed cannabis solutions for its clients. By way of its wholesale and white label platforms, they formulate, customer-test, procedure, package and distribute cannabis extracts and sophisticated cannabinoid-primarily based solutions to domestic and international markets. As a worldwide leader, MediPharm Labs has completed industrial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.
Sponsored Content material Release. Click for Complete Disclosure